Despite the described clear epigenetic effects of smoking, the effect of smoking on genome-wide gene expression in the blood is obscure. We therefore studied the smoking-induced changes in the gene-expression profile of the peripheral blood. RNA was extracted from the whole blood of 48 individuals with a detailed smoking history (24 never-smokers, 16 smokers, and 8 ex-smokers). Gene-expression profiles were evaluated with RNA sequencing, and results were analyzed separately in 24 men and 24 women. In the male smokers, 13 genes were statistically significantly (false-discovery rate <0.1) differentially expressed; in female smokers, 5 genes. Although most of the differentially expressed genes were different between the male and female smokers, the G-protein-coupled receptor 15 gene (GPR15) was differentially expressed in both male and female smokers compared with never-smokers. Analysis of GPR15 methylation identified significantly greater hypomethylation in smokers compared with that in never-smokers. GPR15 is the chemoattractant receptor that regulates T-cell migration and immunity. Up-regulation of GPR15 could explain to some extent the health hazards of smoking with regard to chronic inflammatory diseases.
We
report the development of a rapid, simple, and robust LC–MS/MS-based
enzyme assay using dried blood spots (DBS) for the diagnosis of pyridox(am)ine
5′-phosphate oxidase (PNPO) deficiency (OMIM 610090). PNPO
deficiency leads to potentially fatal early infantile epileptic encephalopathy,
severe developmental delay, and other features of neurological dysfunction.
However, upon prompt treatment with high doses of vitamin B6, affected patients can have a normal developmental outcome. Prognosis
of these patients is therefore reliant upon a rapid diagnosis. PNPO
activity was quantified by measuring pyridoxal 5′-phosphate
(PLP) concentrations in a DBS before and after a 30 min incubation
with pyridoxine 5′-phosphate (PNP). Samples from 18 PNPO deficient
patients (1 day–25 years), 13 children with other seizure disorders
receiving B6 supplementation (1 month–16 years),
and 37 child hospital controls (5 days–15 years) were analyzed.
DBS from the PNPO-deficient samples showed enzyme activity levels
lower than all samples from these two other groups as well as seven
adult controls; no false positives or negatives were identified. The
method was fully validated and is suitable for translation into the
clinical diagnostic arena.
The aim of our study was to evaluate the prevalence of long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) in the general Estonian population and among patients with symptoms suggestive of fatty acid oxidation (FAO) defects. We collected DNA from a cohort of 1,040 anonymous newborn blood spot samples. We screened these samples for the presence of the common c.1528G>C mutation in the HADHA gene. Based on the clinical suspicion of FAO defects, we screened suspected individuals since 2004 for the common c.1528G>C mutation in the HADHA gene and since 2008 in addition by tandem mass spectrometric analysis of plasma acylcarnitines. Our results showed that the carrier frequency of the c.1528G>C mutation in the Estonian population is high -1:173. During the screening of symptomatic patients, we identified five LCHADD patients in four families. Three patients were retrospectively identified by molecular screening of the HADHA gene.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.